Vertex 2024 product revenue $11.02B (+12% YoY); GAAP loss $536M from IPR&D; FY2025 guidance $11.75-12.0B

VERTEX PHARMACEUTICALS INC / MA

2024-FY EPS reported -$2.08 revenue$11,020,100,000

Q4 product revenue $2.91B (+16% YoY); full-year product revenue $11.02B (+12%) driven by TRIKAFTA/KAFTRIO.
GAAP net loss $536M for 2024 due to $4.4B AIPR&D from Alpine Immune Sciences acquisition; non-GAAP net income $111M.
FY2025 total revenue guidance $11.75-12.0B; combined non-GAAP R&D, AIPR&D, SG&A expenses guided at $4.9-5.0B.
COO Stuart Arbuckle retiring July 1, 2025; CFO Charlie Wagner to add COO role, Duncan McKechnie to become CCO.
JOURNAVX approved Jan 30, 2025 for moderate-to-severe acute pain; ALYFTREK approved Dec 20, 2024 for CF ages 6+.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Duncan J. McKechnie

Chief Commercial Officer

VRTX · VERTEX PHARMACEUTICALS INC / MA

Effective: 2025-07-01
Filed: February 10, 2025, 6:59 PM ET

the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company

Role change

Charles F. Wagner, Jr.

Chief Operating Officer

VRTX · VERTEX PHARMACEUTICALS INC / MA

Effective: 2025-07-01
Filed: February 10, 2025, 6:59 PM ET

The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company

Departed

Stuart A. Arbuckle

Executive Vice President and Chief Operating Officer

VRTX · VERTEX PHARMACEUTICALS INC / MA

Effective: 2025-07-01
Successor: Charles F. Wagner, Jr.
Filed: February 10, 2025, 6:59 PM ET

On February 10, 2025, Vertex Pharmaceuticals Incorporated (the “Company”) announced the retirement of Stuart A. Arbuckle, the Company’s Executive Vice President and Chief Operating Officer, effective on July 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Duncan J. McKechnie was appointed as Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA.

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles F. Wagner, Jr. was appointed as Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stuart A. Arbuckle retired as Executive Vice President and Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.

Action: retired
Role: Executive Vice President and Chief Operating Officer

Exact text from the filing

On February 10, 2025, Vertex Pharmaceuticals Incorporated (the “Company”) announced the retirement of Stuart A. Arbuckle, the Company’s Executive Vice President and Chief Operating Officer, effective on July 1, 2025.

View on SEC.gov

VERTEX PHARMACEUTICALS INC / MA filing history →

Source: SEC EDGAR

accession 0000875320-25-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.